Table 7. Assessment of Tumor Response^*.

	RECIST		mRECIST
Target lesion response
CR	Disappearance of all target lesions		Disappearance of any intratumor arterial enhancement in all target lesions
PR	At least a 30% decrease in the sum of the diameters of target lesions, taking the baseline sum of the diameters of target lesions as a reference		At least a 30% decrease in the sum of the diameters of viable (enhancement in the arterial phase) target lesions, taking the baseline sum of the diameters of target lesions as a reference
SD	Any case that does not qualify for either PR or PD		Any case that does not qualify for either PR or PD
PD	An increase of at least 20% in the sum of the diameters of target lesions, taking the smallest sum of the diameters of target lesions recorded since treatment started as a reference		An increase of at least 20% in the sum of the diameters of viable (enhancing) target lesions, taking the smallest sum of the diameters of viable (enhancing) target lesions recorded since treatment started as a reference
Nontarget lesions response
CR	Disappearance of all nontarget lesions		Disappearance of any intratumor arterial enhancement in all nontarget lesions
IR/SD	Persistence of one or more nontarget lesions		Persistence of intratumor arterial enhancement in one or more nontarget lesions
PD	Appearance of one or more new lesions and/or unequivocal progression of existing nontarget lesions		Appearance of one or more new lesions and/or unequivocal progression of existing nontarget lesions

^*Adapted from J Hepatol 2012;56:908-943 (58) and Semin Liver Dis 2010;30:52-60 (498). CR = complete response, HCC = hepatocellular carcinoma, IR = incomplete response, mRECIST = modified RECIST, PD = progressive disease, PR = partial response, RECIST = Response Evaluation Criteria in Solid Tumors, SD = stable disease